Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen

Jonathan A.G. Cox, Grace Mugumbate, Laura Vela-Glez del Peral, Monika Jankute, Katherine A. Abrahams, Peter Jervis, Stefan Jackenkroll, Arancha Perez, Carlos Alemparte, Jorge Esquivias, Joël Lelièvre, Fernando Ramon, David Barros, Lluis Ballell, Gurdyal S. Besra*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identified compounds lack the desired characteristics necessary for further development into lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds were identified in a single shot high-throughput screen, validated by dose response and subjected to further biochemical analysis. The compounds were also assessed using molecular docking experiments, providing a platform for their further optimisation using medicinal chemistry. This work demonstrates the versatility and potential of GuaB2 as an anti-tubercular drug target.

Original languageEnglish
Article number38986
Number of pages10
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 16 Dec 2016

Fingerprint

Pharmaceutical Chemistry
Mycobacterium bovis
Mycobacterium tuberculosis
Inosine Monophosphate
Pharmaceutical Preparations
Oxidoreductases
Anti-Bacterial Agents
Technology
Proteins
Lead

Bibliographical note

© The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Funding: Personal Research Chair from Mr. James Bardrick, a Royal Society Wolfson Research Merit Award; MRC (MR/K012118/1); FP7-2007–2013 (ORCHID no. 261378); BBSRC for an Industrial CASE Studentship in collaboration with the Institute of Microbiology and Infection, University of Birmingham and Diseases of the Developing World, GSK, Tres Cantos, Madrid; and EMBL and Marie Curie Actions.

Cite this

Cox, J. A. G., Mugumbate, G., Vela-Glez del Peral, L., Jankute, M., Abrahams, K. A., Jervis, P., ... Besra, G. S. (2016). Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. Scientific Reports, 6, [38986]. https://doi.org/10.1038/srep38986
Cox, Jonathan A.G. ; Mugumbate, Grace ; Vela-Glez del Peral, Laura ; Jankute, Monika ; Abrahams, Katherine A. ; Jervis, Peter ; Jackenkroll, Stefan ; Perez, Arancha ; Alemparte, Carlos ; Esquivias, Jorge ; Lelièvre, Joël ; Ramon, Fernando ; Barros, David ; Ballell, Lluis ; Besra, Gurdyal S. / Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. In: Scientific Reports. 2016 ; Vol. 6.
@article{106a97595b2a4feb9d73253e49c69936,
title = "Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen",
abstract = "High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identified compounds lack the desired characteristics necessary for further development into lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds were identified in a single shot high-throughput screen, validated by dose response and subjected to further biochemical analysis. The compounds were also assessed using molecular docking experiments, providing a platform for their further optimisation using medicinal chemistry. This work demonstrates the versatility and potential of GuaB2 as an anti-tubercular drug target.",
author = "Cox, {Jonathan A.G.} and Grace Mugumbate and {Vela-Glez del Peral}, Laura and Monika Jankute and Abrahams, {Katherine A.} and Peter Jervis and Stefan Jackenkroll and Arancha Perez and Carlos Alemparte and Jorge Esquivias and Jo{\"e}l Leli{\`e}vre and Fernando Ramon and David Barros and Lluis Ballell and Besra, {Gurdyal S.}",
note = "{\circledC} The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Funding: Personal Research Chair from Mr. James Bardrick, a Royal Society Wolfson Research Merit Award; MRC (MR/K012118/1); FP7-2007–2013 (ORCHID no. 261378); BBSRC for an Industrial CASE Studentship in collaboration with the Institute of Microbiology and Infection, University of Birmingham and Diseases of the Developing World, GSK, Tres Cantos, Madrid; and EMBL and Marie Curie Actions.",
year = "2016",
month = "12",
day = "16",
doi = "10.1038/srep38986",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Cox, JAG, Mugumbate, G, Vela-Glez del Peral, L, Jankute, M, Abrahams, KA, Jervis, P, Jackenkroll, S, Perez, A, Alemparte, C, Esquivias, J, Lelièvre, J, Ramon, F, Barros, D, Ballell, L & Besra, GS 2016, 'Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen', Scientific Reports, vol. 6, 38986. https://doi.org/10.1038/srep38986

Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen. / Cox, Jonathan A.G.; Mugumbate, Grace; Vela-Glez del Peral, Laura; Jankute, Monika; Abrahams, Katherine A.; Jervis, Peter; Jackenkroll, Stefan; Perez, Arancha; Alemparte, Carlos; Esquivias, Jorge; Lelièvre, Joël; Ramon, Fernando; Barros, David; Ballell, Lluis; Besra, Gurdyal S.

In: Scientific Reports, Vol. 6, 38986, 16.12.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen

AU - Cox, Jonathan A.G.

AU - Mugumbate, Grace

AU - Vela-Glez del Peral, Laura

AU - Jankute, Monika

AU - Abrahams, Katherine A.

AU - Jervis, Peter

AU - Jackenkroll, Stefan

AU - Perez, Arancha

AU - Alemparte, Carlos

AU - Esquivias, Jorge

AU - Lelièvre, Joël

AU - Ramon, Fernando

AU - Barros, David

AU - Ballell, Lluis

AU - Besra, Gurdyal S.

N1 - © The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ Funding: Personal Research Chair from Mr. James Bardrick, a Royal Society Wolfson Research Merit Award; MRC (MR/K012118/1); FP7-2007–2013 (ORCHID no. 261378); BBSRC for an Industrial CASE Studentship in collaboration with the Institute of Microbiology and Infection, University of Birmingham and Diseases of the Developing World, GSK, Tres Cantos, Madrid; and EMBL and Marie Curie Actions.

PY - 2016/12/16

Y1 - 2016/12/16

N2 - High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identified compounds lack the desired characteristics necessary for further development into lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds were identified in a single shot high-throughput screen, validated by dose response and subjected to further biochemical analysis. The compounds were also assessed using molecular docking experiments, providing a platform for their further optimisation using medicinal chemistry. This work demonstrates the versatility and potential of GuaB2 as an anti-tubercular drug target.

AB - High-throughput phenotypic screens have re-emerged as screening tools in antibiotic discovery. The advent of such technologies has rapidly accelerated the identification of ‘hit’ compounds. A pre-requisite to medicinal chemistry optimisation programmes required to improve the drug-like properties of a ‘hit’ molecule is identification of its mode of action. Herein, we have combined phenotypic screening with a biased target-specific screen. The inosine monophosphate dehydrogenase (IMPDH) protein GuaB2 has been identified as a drugable target in Mycobacterium tuberculosis, however previously identified compounds lack the desired characteristics necessary for further development into lead-like molecules. This study has identified 7 new chemical series from a high-throughput resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2. Hit compounds were identified in a single shot high-throughput screen, validated by dose response and subjected to further biochemical analysis. The compounds were also assessed using molecular docking experiments, providing a platform for their further optimisation using medicinal chemistry. This work demonstrates the versatility and potential of GuaB2 as an anti-tubercular drug target.

UR - http://www.nature.com/articles/srep38986

UR - http://www.scopus.com/inward/record.url?scp=85006413317&partnerID=8YFLogxK

U2 - 10.1038/srep38986

DO - 10.1038/srep38986

M3 - Article

C2 - 27982051

AN - SCOPUS:85006413317

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 38986

ER -